Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Chembio DPP™ Zika IgM Assay System
The 15-minute rapid test for detecting Zika virus infection
Supplier: Chembio 6595550
Includes: 20 Individually Pouched DPP™ Zika IgM Test Devices, 20 Disposable 10μL Microsafe™ Tubes, 20 Sample Vials, 20 Transfer Pipets (100μL), 1 DPP IgM Sample Buffer, Blue Cap, 1 DPP IgM Running Buffer, Yellow Cap, 1 Product Insert, 1 Quick Reference Guide, Fact sheet for patients, Fact sheet for Health care workers
Description
- Fast: Provides results in as little as 15 minutes
- Flexible: Detects Zika virus IgM antibodies from 8 days up to 12 weeks
- Easy to Use: Provides objective results using simple, handheld digital reader (DPP™ Micro Reader)
- Received FDA Emergency Use Authorization (EUA)
Specifications
| 2°C to 8°C | |
| Rapid Test | |
| 20 Individually Pouched DPP™ Zika IgM Test Devices, 20 Disposable 10μL Microsafe™ Tubes, 20 Sample Vials, 20 Transfer Pipets (100μL), 1 DPP IgM Sample Buffer, Blue Cap, 1 DPP IgM Running Buffer, Yellow Cap, 1 Product Insert, 1 Quick Reference Guide, Fact sheet for patients, Fact sheet for Health care workers | |
| 15 min. |
| Zika Virus IgM | |
| Detection of Zika virus infection in Fingerstick Whole Blood, Venous Whole blood, Serum, Plasma | |
| 20 |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
i. The test has not been FDA cleared or approved;
ii. The test has been authorized by FDA under an EUA for use by authorized laboratories;
iii. The text has been authorized only for the diagnosis of Zika virus infection and not for any other viruses or pathogens;
iv. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of the Zika virus and/or diagnosis of Zika virus infection under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Spot an opportunity for improvement?